Involvement of prolylcarboxypeptidase in the effect of rutaecarpine on the regression of mesenteric artery hypertrophy in renovascular hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 3, 2009, Pages 319-324

  Qin, Xu Ping ^a   Zeng, Si Yu ^a,d   Tian, Hai Hong ^a   Deng, Shui Xiu ^a   Ren, Jun Fang ^a   Zheng, Yuan Bin ^a   Li, Dai ^b   Li, Yuan Jian ^b   Liao, Duan Fang ^a   Chen, Shi You ^c  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF GEORGIA   (United States)

^d Fourth Hospital of Changsha   (China)

Author keywords

Prolylcarboxypeptidase; Rat; Renohypertension; Rutaecarpine; Vascular remodelling

Indexed keywords

ANGIOTENSIN II; KALLIKREIN; KININ; LOSARTAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROLINE CARBOXYPEPTIDASE; RUTAECARPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERY DIAMETER; ARTERY MEDIA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; HORMONE BLOOD LEVEL; HYPERTROPHY; KALLIKREIN KININ SYSTEM; KIDNEY ARTERY; LOW DRUG DOSE; MALE; MESENTERIC ARTERY; MORNING DOSAGE; NONHUMAN; PROTEIN EXPRESSION; RAT; RENOVASCULAR HYPERTENSION; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBOXYPEPTIDASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION, RENOVASCULAR; HYPERTROPHY; INDOLE ALKALOIDS; KALLIKREINS; LOSARTAN; MALE; MESENTERIC ARTERIES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; UP-REGULATION;

EID: 61349139985     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05079.x     Document Type: Article

References (28)

1. Wang QZ, Liang JY. Studies on the chemical constituents of Evodia rutaecarpa (Juss.) Benth. Acta Pharmaceut. Sin. 2004 39 : 605 8.
2. Yu J, Tan GS, Deng PY et al. Involvement of CGRP in the inhibitory effect of rutaecarpine on vasoconstriction induced by anaphylaxis in guinea pig. Regul. Pept. 2005 125 : 93 7.
3. Deng PY, Ye F, Cai WJ et al. Stimulation of calcitonin gene-related peptide synthesis and release: Mechanisms for a novel antihypertensive drug, rutaecarpine. J. Hypertens. 2004 22 : 1819 29.
4. Qin XP, Zeng SY, Li D et al. Calcitonin gene-related peptide-mediated depressor effect and inhibiting vascular hypertrophy of rutaecarpine in renovascular hypertensive rats. J. Cardiovasc. Pharmacol. 2007 50 : 654 9.
5. Wang GJ, Wu XC, Chen CF et al. Vasorelaxing action of rutaecarpine: Effects of rutaecarpine on calcium channel activities in vascular endothelial and smooth muscle cells. J. Pharmacol. Exp. Ther. 1999 289 : 1237 44.
6. Marcondes S, Antunes E. The plasma and tissue kininogen-kallikrein-kinin system: Role in the cardiovascular system. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2005 3 : 33 44.
7. Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp. Physiol. 2005 90 : 291 8.
8. Majima M, Katori M, Hanazuka M et al. Suppression of rat deoxycorticosterone salt hypertension by kallikrein-kinin system. Hypertension 1991 17 : 806 13.
9. Nolly H, Carretero OA, Scicli G et al. A kallikrein-like enzyme in blood vessels of one-kidney, one-clip hypertensive rats. Hypertension 1990 16 : 436 40.
10. Bledsoe G, Chao L, Chao J. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2003 285 : H1479 88.
11. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005 111 : 315 20.
12. Iwai. NH, Yasui. N, Naraba. H et al. Klk1 as one of the genes contributing to hypert ension in Dahl salt-sensitive rat. Hypertension 2005 45 : 947 53.
13. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension. Role of apoptosis, inflammation and fibrosis. Hypertension 2001 38 : 581 7.
14. Qin XP, Long G, Xu LP et al. Comparison of effects of losartan and perindopril on cardiovascular remodeling in losartan renovascular hypertension. Chin. Pharmacol. Bull. 2004 20 : 1107 11.
15. Chao. J, Chao L. Antisense inhibition of the brain kallikrein-kinin system. Hypertension 1996 28 : 980 7.
16. Komine N, Khang S, Wead LM et al. Effect of combining an ACE inhibitior and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am. J. Kidney Dis. 2002 39 : 159 64.
17. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev. 2000 52 : 639 72.
18. Carretero OA. Vascular remodeling and the kallikrein-kinin system. J. Clin. Invest. 2005 115 : 589 91.
19. Wolf WC, Harley RA, Sluce D et al. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J. Histochem. Cytochem. 1999 47 : 221 8.
20. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 2002 277 : 17 962 9.
21. Shariat-Madar Z, Rahimy E, Mahdi F, Schmaier AH. Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. Am. J. Physiol. Heart Circ. Physiol. 2005 289 : H2697 703.
22. Broshinan KB, Li P, Ferrario CM. Angiotensin (1-7) dilatescanine coronary arteries through kinins and nitric oxide. Hypertension 1996 27 : 523 8.
23. Li P, Chappell MC, Ferrario CM. Angiotensin (1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 1997 29 : 394 400.
24. Ueda S, Masumori-Maemoto S, Ashino K et al. Angiotensin (1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 2000 35 : 998 1001.
25. Rizzoni D, Porteri E, Guefi D et al. Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 2000 35 : 931 5.
26. Santos RAS, Brosnihan KB, Jacobsen DW et al. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 1992 19 : 56 61.
27. Marcic BM, Erdos EG. Protein kinase C and phosphatase inhibitiors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J. Pharmacol. Exp. Ther. 2000 294 : 605 12.
28. Qin XP, Ye F, Liao DF et al. Involvement of calcitonin gene-related peptide in the depressor effects of losartan and perindopril in rats. Eur. J. Pharmacol. 2003 464 : 63 7.